Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice

Progress in Neuro-psychopharmacology & Biological Psychiatry
B Ribeiro Do CoutoJ Miñarro

Abstract

Several studies have shown that the systemic administration of a variety of N-methyl-D-aspartate (NMDA) receptor antagonists can block the development or expression of conditioned place preference (CPP) induced by rewarding drugs such as morphine. In the present study, we examined the effects of different doses of two non-competitive NMDA receptor antagonists, MK-801 (0.1, 0.2 and 0.3 mg/kg) and memantine (2.5, 5, 10, 20 and 40 mg/kg), in CPP induced by 40 mg/kg of morphine in male mice. The CPP was carried out with an unbiased procedure in terms of initial spontaneous preference. Animals received the different doses of drugs in the conditioning sessions. MK-801 and memantine, at all doses used, produced neither place preference nor place aversion, but the higher doses of memantine (20 and 40 mg/kg) were able to completely block morphine-induced CPP. The present data show that the NMDA receptor antagonists MK-801 and memantine have no reinforcing properties but memantine is capable of preventing the acquisition of morphine-induced CPP. These results suggest that the development of morphine-induced CPP may be closely related to NMDA receptors and that the glutamatergic system can modulate opiate reward.

References

Jun 1, 1991·Pharmacology, Biochemistry, and Behavior·P LeoneR A Wise
Sep 1, 1989·Behavioural Brain Research·D Corbett
Jan 1, 1993·Pharmacology, Biochemistry, and Behavior·R T LayerL J Wallace
May 27, 1999·Naunyn-Schmiedeberg's Archives of Pharmacology·P Popik, W Kolasiewicz
Nov 5, 1999·Pharmacology, Biochemistry, and Behavior·J J PanosR E Steinpreis
Mar 17, 2001·Nature Reviews. Neuroscience·E J Nestler
Oct 9, 2002·Current Medicinal Chemistry·M S Levi, R F Borne
Nov 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Marius PappPaul Willner
Feb 22, 2003·Naunyn-Schmiedeberg's Archives of Pharmacology·M J Cano-CebriánL Granero
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Piotr PopikBarbara S Slusher

❮ Previous
Next ❯

Citations

Dec 30, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Shiou-Lan ChenRu-Band Lu
Jun 26, 2012·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Shiou-Lan ChenJau-Shyong Hong
Jul 16, 2010·Expert Opinion on Investigational Drugs·Marta Rodríguez-AriasJosé Miñarro
Mar 28, 2008·Substance Use & Misuse·Daniele F Zullino, Yasser Khazaal
Sep 3, 2008·Brain Research Reviews·Maria A AguilarJose Miñarro
Apr 29, 2008·Brain Research Reviews·Teresa Cunha-OliveiraCatarina R Oliveira
May 19, 2007·European Journal of Pharmacology·Mohammad-Reza ZarrindastFarzaneh Nazari-Serenjeh
Mar 31, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·C MaldonadoJ Miñarro
Dec 23, 2006·Brain Research·Ameneh RezayofMohammad-Reza Zarrindast
May 25, 2010·Alcoholism, Clinical and Experimental Research·Brandon G OberlinNicholas J Grahame
Jul 15, 2009·Brain Research·María A AguilarJosé Miñarro
Jun 14, 2006·Behavioural Brain Research·Fanny BotreauJane Stewart
Jun 17, 2006·Pharmacology, Biochemistry, and Behavior·Meredith A FoxAnthony L Riley
Jul 26, 2005·Peptides·Richard J Bodnar, Gad E Klein
Jun 22, 2005·Brain Research·B Ribeiro Do CoutoJ Miñarro
Sep 17, 2014·Neurobiology of Learning and Memory·Yasaman AlaghbandJohn F Marshall
Jul 1, 2011·Drug and Alcohol Dependence·Adam BisagaEdward V Nunes
Oct 10, 2013·The International Journal of Neuropsychopharmacology·Sheng-Yu LeeRu-Band Lu
Nov 28, 2013·Pharmaceuticals·Seven E TomekM Foster Olive
Aug 23, 2011·Pharmacological Reports : PR·Kambiz HassanzadehSadollah Mohammadi
Sep 23, 2014·Jundishapur Journal of Natural Pharmaceutical Products·Mohsen ImenshahidiHossein Hosseinzadeh
Apr 29, 2020·Cold Spring Harbor Perspectives in Medicine·Jasper A HeinsbroekJamie Peters

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.